Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
ISOSORBIDE MONONITRATE
Primecrown Ltd.
ISOSORBIDE MONONITRATE
60 Milligram
Tablets
Withdrawn
2010-10-07
PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Imdur 60 mg prolonged release film-coated tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Isosorbide mononitrate 60 mg. For excipients, see 6.1. 3 PHARMACEUTICAL FORM Prolonged release film-coated Tablets. The tablets are scored and are marked “A” and “ID” on one side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Prophylactic management of angina pectoris. Imdur is not indicated in the management of acute attacks of angina pectoris. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Imdur 60 mg once daily to be taken in the morning. The dose may be increased to 120 mg daily, the whole dose to be given together in the morning. This will produce effective nitrate blood levels during the day with low blood levels at night to prevent the development of tolerance. The dose can be titrated to minimise the possibility of headache, by initiating treatment with a 30 mg dose, for the first two to four days. Whole Imdur tablets, or if needed, the divided halves, must not be chewed or crushed. They should be swallowed together with half a glass of water. Note that Imdur is not indicated for the relief of acute attacks, in the event of an acute attack, sublingual or buccal glyceryl trinitrate tablets should be used. CHILDREN The safety and efficacy of Imdur in children has not been established. ELDERLY No evidence of a need for routine dosage adjustment in the elderly has been found, but special care may be needed in those with increased susceptibility to hypotension or marked hepatic or renal insufficiency. An additional anti-anginal effect has been achieved when Imdur has been used in combination with beta-blockers. IRISH MEDICINES BOARD _______________________________________________________________ Read the complete document